Swapping a generic for a brand-name equivalent is settled law in every state. Swapping a patient’s atorvastatin for rosuvastatin because the pharmacy’s contracted formulary prefers it — without calling the prescriber — is a completely different legal question, and the answer depends entirely on which state you’re standing in and what kind of practice setting you’re in.
Generic substitution vs. therapeutic substitution: not the same thing
Generic substitution is dispensing a bioequivalent generic version of the exact drug prescribed (same active ingredient, dose, and route). Every state permits this, subject to state-specific rules on patient/prescriber “dispense as written” notations and generic substitution disclosure requirements.
Therapeutic substitution (or therapeutic interchange) is dispensing a different but therapeutically similar drug — typically within the same class, like substituting one ACE inhibitor for another, or one PPI for another — without a new prescription. This is far more restricted, and in most outpatient community pharmacy settings, a pharmacist cannot do this on their own authority at all.
Where therapeutic substitution is actually permitted
Institutional/hospital settings under a P&T-approved formulary. The most common lawful pathway is inside a hospital or health system, where a Pharmacy and Therapeutics (P&T) committee has pre-approved a formulary with specific therapeutic interchange protocols — for example, automatically substituting a non-formulary PPI for the formulary-preferred one. This is generally permitted in every state because it operates under institutional medical staff bylaws and a physician-approved protocol, not the pharmacist acting unilaterally.
Under a collaborative practice agreement (CPA). In states with robust CPA frameworks, a pharmacist can perform therapeutic substitution for a specific patient under a signed agreement with that patient’s prescriber, specifying which drug classes and substitution rules apply. This is patient-specific and prescriber-specific, unlike a blanket formulary protocol. See our deeper coverage of collaborative practice agreements by state for how these agreements are structured and where they’re recognized.
Emergency or shortage-driven substitution. A number of states have specific statutory allowances for pharmacists to substitute a therapeutically equivalent drug during a documented drug shortage, without needing a new prescription, provided the substitution is logged and the prescriber is notified.
Outside these three pathways, most states do not permit unilateral therapeutic substitution in a standard community retail setting — a pharmacist who swaps drug classes without one of these authorizations is practicing outside scope, even with good clinical intent.
Biosimilars are their own substitution category
Substituting a biosimilar for its reference biologic product is governed by separate state biosimilar substitution laws, not the general therapeutic substitution framework — most states have a specific statute listing which biosimilars are designated “interchangeable” by the FDA and are therefore substitutable at the pharmacy level like a generic, plus state-specific prescriber notification requirements. Don’t apply general therapeutic substitution reasoning to biologics; treat biosimilar substitution as its own compliance question with its own state rules.
Documentation requirements when substitution does occur
Whichever pathway authorizes the substitution, states generally require:
- A record of the specific protocol, CPA, or shortage declaration authorizing the substitution
- Prescriber notification, either before dispensing or within a defined window afterward, depending on the state and pathway
- Patient notification that a substitution occurred, particularly for therapeutic (not generic) substitutions where the active ingredient itself changed
This documentation matters both for board compliance and for pharmacy malpractice insurance purposes — an undocumented therapeutic substitution that leads to an adverse outcome is much harder to defend than one backed by a clear protocol and notification trail.
How this connects to broader prescriptive authority expansion
Therapeutic substitution authority is one piece of a broader trend toward expanding pharmacist prescriptive authority, where states are giving pharmacists more independent clinical decision-making latitude, often paired with pharmacist test-and-treat authority for minor conditions. If you’re tracking scope-of-practice changes generally, therapeutic substitution rules are worth monitoring alongside these related expansions since legislatures often bundle them into the same scope-of-practice bills.
Bottom line
Therapeutic substitution is legally distinct from generic substitution and, outside of hospital formulary protocols, collaborative practice agreements, or shortage-specific statutes, is generally not something a community pharmacist can do unilaterally. Confirm your state’s specific rules and your practice setting’s authorization before substituting across drug classes — this is an area where good clinical judgment doesn’t substitute for legal authority.
RxByState tracks pharmacist scope-of-practice and substitution authority rules across all 50 states. Start a free 14-day trial →